TY - JOUR
T1 - A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574)
AU - Nguyen, Nhu Tram A
AU - Isfahanian, Naghmeh
AU - Pond, Gregory
AU - Hanna, Wael
AU - Cutz, Jean Claude
AU - Wright, James
AU - Swaminath, Anand
AU - Shargall, Yaron
AU - Chow, Tom
AU - Wierzbicki, Marcin
AU - Okawara, Gordon
AU - Quan, Kimmen
AU - Finley, Christian
AU - Juergens, Rosalyn
AU - Tsakiridis, Theodoros
PY - 2017/1/10
Y1 - 2017/1/10
N2 - Background: Despite improved staging and surgical techniques, the rate of incomplete resection (R1) of non-small-cell lung cancer (NSCLC) has not significantly decreased. Patients with R1 resection have worse survival compared with those with complete resection (R0). Stereotactic body radiotherapy (SBRT) is a rapid and convenient radiotherapy treatment that delivers high-dose radiotherapy to tumors with high precision while sparing normal organs. Although its efficacy in treating small lung tumors is documented, its use as neoadjuvant therapy for locally advanced (LA) NSCLC has not been examined. We hypothesized that a short course of preoperative SBRT is feasible and can be delivered safely as a neoadjuvant therapy in patients at risk for incomplete resection. Methods: In this phase I study, 20 patients with cT3 to 4, N0 to 1, M0 NSCLC at risk for incomplete resection will be treated with neoadjuvant SBRT followed by surgery and adjuvant chemotherapy. Four groups of 5 patients will be treated with escalating doses (35, 40, 45, and 50 Gy) in 10 daily fractions. The primary outcome is feasibility (ie, the ability to complete SBRT and surgery as planned; within 7 weeks). Secondary outcomes include acute and late adverse events; R0, R1, and R2 rates; and secondary surrogates of feasibility and safety. Relevance: This study is an important first step in introducing a new therapeutic modality to patients with LA NSCLC that could improve surgical outcomes in the future. If neoadjuvant SBRT is found to be feasible and safe for LA NSCLC, its effect in achieving R0 resection could be investigated in randomized trials.
AB - Background: Despite improved staging and surgical techniques, the rate of incomplete resection (R1) of non-small-cell lung cancer (NSCLC) has not significantly decreased. Patients with R1 resection have worse survival compared with those with complete resection (R0). Stereotactic body radiotherapy (SBRT) is a rapid and convenient radiotherapy treatment that delivers high-dose radiotherapy to tumors with high precision while sparing normal organs. Although its efficacy in treating small lung tumors is documented, its use as neoadjuvant therapy for locally advanced (LA) NSCLC has not been examined. We hypothesized that a short course of preoperative SBRT is feasible and can be delivered safely as a neoadjuvant therapy in patients at risk for incomplete resection. Methods: In this phase I study, 20 patients with cT3 to 4, N0 to 1, M0 NSCLC at risk for incomplete resection will be treated with neoadjuvant SBRT followed by surgery and adjuvant chemotherapy. Four groups of 5 patients will be treated with escalating doses (35, 40, 45, and 50 Gy) in 10 daily fractions. The primary outcome is feasibility (ie, the ability to complete SBRT and surgery as planned; within 7 weeks). Secondary outcomes include acute and late adverse events; R0, R1, and R2 rates; and secondary surrogates of feasibility and safety. Relevance: This study is an important first step in introducing a new therapeutic modality to patients with LA NSCLC that could improve surgical outcomes in the future. If neoadjuvant SBRT is found to be feasible and safe for LA NSCLC, its effect in achieving R0 resection could be investigated in randomized trials.
KW - Borderline resectable NSCLC
KW - Feasibility and safety
KW - Locally advanced non-small-cell lung cancer
KW - Lung cancer surgery
KW - Neoadjuvant SBRT
UR - http://www.scopus.com/inward/record.url?scp=85012895259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012895259&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2017.01.007
DO - 10.1016/j.cllc.2017.01.007
M3 - Article
C2 - 28215851
AN - SCOPUS:85012895259
SN - 1525-7304
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
ER -